Cambridge Cognition and ActiGraph partner to advance digital health technologies in CNS trials

LONDON, UK: Cambridge Cognition Holdings plc, a developer and marketer of digital solutions for brain health assessment, has announced a new strategic partnership with ActiGraph, a leading provider of wearable technologies for clinical trials.

The partnership will deliver a comprehensive suite of assessments to measure mental and physical capabilities in clinical development, especially in areas with a large unmet need, such as schizophrenia and dementia.

The partnership is part of ActiGraph’s AccelerantTM program, which aims to simplify the access to raw data streams from digital health technologies (DHTs) for CROs and technology vendors.

Cambridge Cognition offers accurate and sensitive digital assessments of cognition and other brain health indicators, based on over 30 years of innovation and scientific validation. The company’s e-clinical technology solutions can be used at home or in-clinic, giving flexibility to capture important clinical measures.

Both companies are leaders in their respective markets and have already collaborated with top 20 pharmaceutical companies in clinical trials. The combination of actigraphy data and brain health assessments may enable more accurate multi-modal digital biomarkers in the future.

Francesca Cormack, Chief Scientist, Cambridge Cognition, commented: “CNS disorders are characterised by a host of heterogeneous symptoms which impact daily life, but that are often inadequately addressed by existing treatments. Our partnership with ActiGraph represents an exciting combination of expertise in objective digital measures of actigraphy, speech and cognition that will help accelerate the development of treatments for patients and improve efficiency in clinical trials.”

Christine Guo, Chief Scientific Officer, ActiGraph, commented: “Digital health technologies give us the ability to collect data objectively during a patient’s everyday life. This is especially important in CNS disorders where conventional assessments are prone to subjective biases. We are excited about this partnership with Cambridge Cognition to provide advanced clinical insights to study teams conducting CNS trials.”

Cambridge Cognition acquires Toronto based Winterlight Labs for £7.0 million

Add a Comment

Your email address will not be published. Required fields are marked *